MediPal Holdings Corporation
TSE:7459 주식 보고서
MediPal Holdings 대차 대조표 상태 MediPal Holdings 의 총 주주 지분은 ¥757.7B 이고 총 부채는 ¥0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 ¥1,879.8B 및 ¥1,122.1B 입니다. MediPal Holdings 의 EBIT는 ¥53.9B 이며 이자보상배율은 -18.5 입니다. ¥251.4B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보 이자 보상 비율 -18.5x 현금 JP¥251.39b 주식 JP¥757.65b 총 부채 JP¥1.12t 총 자산 JP¥1.88t
최근 재무 상태 업데이트
모든 업데이트 표시
Consensus EPS estimates increase by 11% Nov 11
New major risk - Revenue and earnings growth Nov 06
Second quarter 2025 earnings released: EPS: JP¥61.05 (vs JP¥28.08 in 2Q 2024) Nov 03
Returns On Capital At MediPal Holdings (TSE:7459) Have Stalled Oct 14
Upcoming dividend of JP¥30.00 per share Sep 20
MediPal Holdings (TSE:7459) Will Pay A Dividend Of ¥30.00 Aug 28
MediPal Holdings Corporation to Report Q2, 2025 Results on Nov 01, 2024 Aug 27
Calculating The Fair Value Of MediPal Holdings Corporation (TSE:7459) Aug 24
MediPal Holdings (TSE:7459) Has Announced A Dividend Of ¥30.00 Aug 06
Dividend of JP¥30.00 announced Aug 06
Now 27% undervalued after recent price drop Aug 05
MediPal Holdings Corporation (TSE:7459) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? Aug 05
First quarter 2025 earnings released: EPS: JP¥42.95 (vs JP¥52.32 in 1Q 2024) Aug 03
MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB Jul 02
MEDIPAL Holdings Corporation and JCR Pharmaceuticals Co., Ltd. Announce Completion of Clinical Trial Notification Process in Japan for Phase I/II Study of JR-446 for Mucopolysaccharidosis Type IIIB Jul 01
Returns On Capital At MediPal Holdings (TSE:7459) Have Hit The Brakes Jun 25
MediPal Holdings Corporation to Report Q1, 2025 Results on Aug 01, 2024 Jun 06
MediPal Holdings Corporation (TSE:7459) completed the acquisition of PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744). Jun 01
Concerns Surrounding MediPal Holdings' (TSE:7459) Performance May 22
Full year 2024 earnings: EPS exceeds analyst expectations May 18
MediPal Holdings Corporation, Annual General Meeting, Jun 25, 2024 May 16 MediPal Holdings Corporation (TSE:7459) announces an Equity Buyback for 2,500,000 shares, representing 1.19% for ¥5,000 million. May 15
Some Confidence Is Lacking In MediPal Holdings Corporation's (TSE:7459) P/E May 08
MediPal Holdings Corporation (TSE:7459) agreed to acquire PreMedica Inc. from Noritsu Koki Co., Ltd. (TSE:7744) for ¥3.8 billion. May 01
Upcoming dividend of JP¥30.00 per share Mar 21
MediPal Holdings Corporation to Report Fiscal Year 2024 Results on May 14, 2024 Mar 02
Third quarter 2024 earnings released: EPS: JP¥52.80 (vs JP¥59.65 in 3Q 2023) Feb 08
MediPal Holdings Corporation to Report Q3, 2024 Results on Feb 05, 2024 Nov 27
Second quarter 2024 earnings released: EPS: JP¥28.08 (vs JP¥43.12 in 2Q 2023) Nov 04
Price target increased by 9.5% to JP¥2,475 Oct 19
Upcoming dividend of JP¥30.00 per share at 2.3% yield Sep 21
MediPal Holdings Corporation to Report Q2, 2024 Results on Nov 02, 2023 Aug 30
First quarter 2024 earnings released: EPS: JP¥52.32 (vs JP¥39.39 in 1Q 2023) Aug 03
Price target increased by 12% to JP¥2,198 Jul 13
MediPal Holdings Corporation to Report Q1, 2024 Results on Aug 02, 2023 May 31
Full year 2023 earnings: EPS exceeds analyst expectations May 17
Consensus EPS estimates increase by 14% May 15
MediPal Holdings Corporation, Annual General Meeting, Jun 27, 2023 May 14
Upcoming dividend of JP¥23.00 per share at 2.6% yield Mar 23
Now 22% undervalued Mar 13
Third quarter 2023 earnings released: EPS: JP¥59.65 (vs JP¥49.09 in 3Q 2022) Feb 02
MediPal Holdings Corporation (TSE:7459) entered into a Share Purchase agreement to acquire Sumitomo Pharma FOOD & CHEMICAL Co., LTD. from Sumitomo Pharma Co., Ltd. (TSE:4506). Dec 01
MediPal Holdings Corporation to Report Q3, 2023 Results on Feb 01, 2023 Nov 30
Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022) Nov 16
Less than half of directors are independent Nov 16
Second quarter 2023 earnings released: EPS: JP¥43.12 (vs JP¥43.25 in 2Q 2022) Nov 02
Upcoming dividend of JP¥23.00 per share Sep 22
MediPal Holdings Corporation to Report Q2, 2023 Results on Oct 31, 2022 Sep 01
First quarter 2023 earnings released: EPS: JP¥39.39 (vs JP¥44.98 in 1Q 2022) Jul 31
MediPal Holdings Corporation to Report Q1, 2023 Results on Jul 29, 2022 Jun 24
Full year 2022 earnings: EPS misses analyst expectations May 19
Investor sentiment deteriorated over the past week May 18
MediPal Holdings Corporation, Annual General Meeting, Jun 24, 2022 May 15
Less than half of directors are independent Apr 27
Upcoming dividend of JP¥21.00 per share Mar 23
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 02
Now 20% undervalued Jan 25
Second quarter 2022 earnings released: EPS JP¥43.25 (vs JP¥23.93 in 2Q 2021) Oct 31
Upcoming dividend of JP¥21.00 per share Sep 22
First quarter 2022 earnings released: EPS JP¥44.98 (vs JP¥32.88 in 1Q 2021) Aug 03
Full year 2021 earnings released: EPS JP¥114 (vs JP¥176 in FY 2020) May 15
Upcoming dividend of JP¥21.00 per share Mar 23
MediPal Holdings Corporation to Report Fiscal Year 2021 Results on May 13, 2021 Mar 06
Third quarter 2021 earnings released: EPS JP¥21.05 (vs JP¥52.72 in 3Q 2020) Feb 03
Revenue and earnings beat expectations Feb 03
New 90-day high: JP¥2,141 Jan 29
Analysts update estimates Jan 19
Analysts update estimates Dec 01
MediPal Holdings Corporation to Report Q3, 2021 Results on Jan 29, 2021 Nov 18
MediPal Holdings Corporation to Report Q2, 2021 Results on Oct 30, 2020 Sep 12 MediPal Holdings Corporation to Report Q1, 2021 Results on Jul 31, 2020 Jun 29
재무 상태 분석
단기부채: 7459 의 단기 자산 ( ¥1,306.8B )이 단기 부채 ( ¥1,062.3B ).
장기 부채: 7459 의 단기 자산( ¥1,306.8B )이 장기 부채 ( ¥59.8B ).
부채 대 자본 내역 및 분석
부채 감소: 7459 는) 부채 대 자기자본 비율이 12.9% 였던 5년 전과 비교하여 부채가 없습니다.
부채 범위: 7459 은 부채가 없으므로 영업현금흐름 으로 충당할 필요가 없습니다.
이자 보장: 7459 에는 부채가 없으므로 이자 지불 에 대한 보장은 문제가 되지 않습니다.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
